Systematic review of cost and cost-effectiveness of different TB-screening strategies.
Standard
Systematic review of cost and cost-effectiveness of different TB-screening strategies. / Nienhaus, Albert; Schablon, Anja; Costa, José Torres; Diel, Roland.
in: BMC HEALTH SERV RES, Jahrgang 11, 2011, S. 247.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Systematic review of cost and cost-effectiveness of different TB-screening strategies.
AU - Nienhaus, Albert
AU - Schablon, Anja
AU - Costa, José Torres
AU - Diel, Roland
PY - 2011
Y1 - 2011
N2 - Interferon-? release assays (IGRAs) for TB have the potential to replace the tuberculin skin test (TST) in screening for latent tuberculosis infection (LTBI). The higher per-test cost of IGRAs may be compensated for by lower post-screening costs (medical attention, chest x-rays and chemoprevention), given the higher specificity of the new tests as compared to that of the conventional TST. We conducted a systematic review of all publications that have addressed the cost or cost-effectiveness of IGRAs. The objective of this report was to undertake a structured review and critical appraisal of the methods used for the model-based cost-effectiveness analysis of TB screening programmes.
AB - Interferon-? release assays (IGRAs) for TB have the potential to replace the tuberculin skin test (TST) in screening for latent tuberculosis infection (LTBI). The higher per-test cost of IGRAs may be compensated for by lower post-screening costs (medical attention, chest x-rays and chemoprevention), given the higher specificity of the new tests as compared to that of the conventional TST. We conducted a systematic review of all publications that have addressed the cost or cost-effectiveness of IGRAs. The objective of this report was to undertake a structured review and critical appraisal of the methods used for the model-based cost-effectiveness analysis of TB screening programmes.
KW - Germany
KW - Humans
KW - Male
KW - Female
KW - Cost-Benefit Analysis
KW - Contact Tracing/economics/methods
KW - Health Care Costs
KW - Interferon-gamma Release Tests/economics/methods
KW - Mass Screening/economics/methods
KW - Tuberculin Test/economics/methods
KW - Tuberculosis, Pulmonary/diagnosis/economics/epidemiology
KW - Germany
KW - Humans
KW - Male
KW - Female
KW - Cost-Benefit Analysis
KW - Contact Tracing/economics/methods
KW - Health Care Costs
KW - Interferon-gamma Release Tests/economics/methods
KW - Mass Screening/economics/methods
KW - Tuberculin Test/economics/methods
KW - Tuberculosis, Pulmonary/diagnosis/economics/epidemiology
U2 - 10.1186/1472-6963-11-247
DO - 10.1186/1472-6963-11-247
M3 - SCORING: Journal article
VL - 11
SP - 247
JO - BMC HEALTH SERV RES
JF - BMC HEALTH SERV RES
SN - 1472-6963
ER -
